BMS swooped on Karuna towards the end of last year, shortly after AbbVie agreed an $8.7 billion deal to acquire Cerevel Therapeutics, another company developing a schizophrenia drug with a novel ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics in 2023 and the drug's approval last September ended a decades-long drought in new-mechanism therapies for ...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies ...

Get the latest news and real-time alerts from Bristol-Myers Squibb Company (BMY) stock at Seeking Alpha.

Market: Open Tenaya Therapeutics, Inc. Common Stock (TNYA) Bid: $0.6005 X 600 Ask: $0.6033 X 452 Volume: 1,212,269 ...